Elevated C-reactive protein and cardiovascular risk
Current Opinion in Cardiology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 27, 2025
Purpose
of
review
This
critically
examines
the
evolving
role
C-reactive
protein
(CRP)
in
cardiovascular
disease
(CVD),
addressing
its
pathogenesis
and
relationship
with
various
CVDs
including
coronary
artery
(CAD),
heart
failure,
atrial
fibrillation.
Recent
findings
CRP
is
mechanistically
implicated
endothelial
dysfunction,
oxidative
stress,
plaque
destabilization.
studies
demonstrate
that
lipid-lowering
agents
(statins,
bempedoic
acid)
anti-inflammatory
therapies
(canakinumab,
colchicine)
reduce
levels
improve
outcomes
CAD.
In
elevated
predicts
adverse
events,
though
evidence
on
phenotypes
varies,
novel
(glucagon-like
peptide-1
agonists,
sodium-glucose
cotransporter-2
inhibitors)
lower
independently
weight
loss.
For
fibrillation,
correlates
postoperative
incidence
recurrence
postablation,
data
remain
inconsistent.
Guidelines
offer
differing
opinion
American
College
Cardiology
Heart
Association
(ACC/AHA)
guidelines
cautiously
endorsing
for
risk
stratification
intermediate-risk
individuals,
while
European
advise
against
routine
use
primary
prevention,
reflecting
unresolved
questions
about
CRP's
additive
value.
Summary
remains
a
pivotal
inflammation
biomarker
CVD,
yet
causal
clinical
applicability
require
clarification.
While
CRP-guided
show
promise,
discrepancies
highlight
need
robust
trials
to
determine
whether
targeting
directly
improves
outcomes.
Future
research
should
focus
pathophysiological
mechanisms
validate
utility
personalized
CVD
management.
Language: Английский
Relationship Between Epicardial Adipose Tissue and Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction
Cureus,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 19, 2025
Introduction
and
aim:
Heart
failure
with
preserved
ejection
fraction
(HFpEF)
is
a
significant
clinical
challenge,
often
coexisting
atrial
fibrillation
(AF),
which
exacerbates
patient
outcomes
by
increasing
risks
of
stroke,
hospitalizations,
mortality.
Recent
studies
suggest
that
epicardial
adipose
tissue
(EAT),
metabolically
active
fat
depot,
may
contribute
to
AF
pathogenesis
promoting
remodeling
fibrosis.
This
study
aimed
evaluate
the
relationship
between
EAT
thickness
in
HFpEF
patients.
Materials
methods:
A
total
110
patients
were
included,
20
(18.2%)
having
documented
AF.
was
measured
using
transthoracic
echocardiography,
confirmed
via
electrocardiography.
Results:
Patients
had
significantly
greater
compared
those
without
(8.3
±
0.9
mm
vs.
7.1
0.8
mm,
p
<
0.001).
Receiver
operating
characteristic
(ROC)
analysis
demonstrated
strong
predictor
(AUC
=
0.87,
0.001),
cut-off
value
7.5
achieving
89%
sensitivity
75%
specificity.
Conclusion:
These
findings
indicate
increased
independently
associated
patients,
highlighting
its
potential
as
biomarker
for
risk
stratification.
Future
should
explore
whether
targeting
could
improve
this
high-risk
population.
Language: Английский